selected publications
-
academic article
-
The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma.
Melanoma Research.
28.
2018
Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016.
Journal of Translational Medicine.
15.
2017
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
The Lancet Oncology.
18.
2017
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts.
Journal of Translational Medicine.
15.
2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
The Lancet Oncology.
18.
2017
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.
Clinical Cancer Research.
23.
2017
1106O Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL).
Annals of Oncology.
27.
2016
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one.
Journal for ImmunoTherapy of Cancer.
4.
2016
Cancer Immunotherapy: from the lab to clinical applications. Potential impact on cancer centres’ organisation.
Ecancermedicalscience.
10.
2016
LBA2_PR melanoma and other skin tumours Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial.
Annals of Oncology.
27.
2016
Melanoma and immunotherapy bridge 2015.
Journal of Translational Medicine.
14.
2016
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
The Lancet Oncology.
16.
2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
New England Journal of Medicine.
373.
2015
Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma.
Journal of Translational Medicine.
13.
2015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
The Lancet Oncology.
16.
2015
Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma.
American Journal of Therapeutics.
22.
2015
Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial..
Journal of Clinical Oncology.
32.
2014
Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial..
Journal of Clinical Oncology.
32.
2014
-
hide from search